SARS-CoV-2 Spike antibody (B.1.1.7 - alpha, P681H)

Catalog No. ABIN6992311

Product Details anti-SARS-CoV-2 Spike Antibody

Target: SARS-CoV-2 Spike

Binding Specificity: B.1.1.7 - alpha, P681H

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS CoV-2 Alpha

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SARS-CoV-2 Spike antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Purification: SARS-CoV-2 UK Variant (B.1.1.7) Spike P681H antibody is affinity chromatography purified via peptide column.

Immunogen: Anti-SARS-CoV-2 UK Variant (B.1.1.7) Spike P681H antibody was raised against a peptide corresponding to 12 amino acids near the center of SARS-CoV-2 UK variant (B.1.1.7) Spike protein. The immunogen is located within 650-700 amino acids of SARS-CoV-2 UK variant (B.1.1.7) Spike protein.

Isotype: IgG

Application Details

Application Notes: WB: 1 μ,g/mL. Antibody validated: Western Blot in human samples. Anti-SARS-CoV-2 UK Variant (B.1.1.7) Spike P681H antibody can specifically detect SARS-CoV-2 UK Variant (B.1.1.7) Spike S1 protein, but not SARS-CoV-2 WT Spike S1 protein by ELISA. It can also detect mutant peptide (681H), but not WT peptide (681P). All other applications and species not yet tested.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: SARS-CoV-2 UK Variant (B.1.1.7) Spike P681H antibody is supplied in PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,4 °C

Storage Comment: SARS-CoV-2 UK Variant (B.1.1.7) Spike P681H antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for SARS-CoV-2 Spike

Target: SARS-CoV-2 Spike

Abstract: SARS-CoV-2 Spike Products

Synonyms: E2 antibody, E2 glycoprotein precursor antibody, Surface Glycoprotein antibody, S antibody

Target Type: Viral Protein

Background:

In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50 % . Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein.

Gene ID: 43740568